{"id":{"repo_id":"debrecen","oai_identifier":"oai:dea.lib.unideb.hu:2437/353054"},"canonical_url":"https://search.dev.ndltd.org/etd/debrecen/oai:dea.lib.unideb.hu:2437/353054","repository":{"repo_id":"debrecen","name":"University of Debrecen","base_url":"https://dea.lib.unideb.hu/server/oai/request"},"display":{"title":"Treatment approaches to chronic decompensated heart failure","abstract":"Heart failure remains, to this day, a clinical challenge for both patients and clinicians. For stage A and B patients, lifestyle changes, healthier diets, risk factors control, and comorbidities management are recommended. In stage C, aside from the general management in stages A and B are considered, medications like MRA, ACE-I, Beta-blockers, and SGLT2i, which are the four pillars of GDMT, should be recommended due to their great benefit on the disease’s outcome. Besides GDMT, for specific cases, different medications, as well as device methods, should be considered. Unfortunately, some patients will eventually progress into the advanced stage (stage D) of HF. The general treatment in this stage of the disease consists mainly of inotropic medications and short-term and long-term mechanical circulatory support, with heart transplantation as the gold standard. Patients with advanced heart failure who are not eligible for heart transplantation or long-term mechanical circulatory support should be considered for palliative therapy.","abstract_html":"Heart failure remains, to this day, a clinical challenge for both patients and clinicians. For stage A and B patients, lifestyle changes, healthier diets, risk factors control, and comorbidities management are recommended. In stage C, aside from the general management in stages A and B are considered, medications like MRA, ACE-I, Beta-blockers, and SGLT2i, which are the four pillars of GDMT, should be recommended due to their great benefit on the disease’s outcome. Besides GDMT, for specific cases, different medications, as well as device methods, should be considered. Unfortunately, some patients will eventually progress into the advanced stage (stage D) of HF. The general treatment in this stage of the disease consists mainly of inotropic medications and short-term and long-term mechanical circulatory support, with heart transplantation as the gold standard. Patients with advanced heart failure who are not eligible for heart transplantation or long-term mechanical circulatory support should be considered for palliative therapy.","abstract_has_math":false,"creators":["Phan, Tai Anh Hao"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"DE--Általános Orvostudományi Kar","school":null,"contributors":[],"advisors":["Pórszász, Róbert"],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-07-27T19:14:01Z","subjects":["Chronic decompensated heart failure","Treatment"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2437/353054","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Pórszász, Róbert"]},{"key":"dc:contributor.department","label":"Department","values":["DE--Általános Orvostudományi Kar"]},{"key":"dc:creator","label":"Author","values":["Phan, Tai Anh Hao"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2023-05-11T11:21:45Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2023-05-11T11:21:45Z"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chronic decompensated heart failure","Treatment"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2437/353054"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Heart failure remains, to this day, a clinical challenge for both patients and clinicians. For stage A and B patients, lifestyle changes, healthier diets, risk factors control, and comorbidities management are recommended. In stage C, aside from the general management in stages A and B are considered, medications like MRA, ACE-I, Beta-blockers, and SGLT2i, which are the four pillars of GDMT, should be recommended due to their great benefit on the disease’s outcome. Besides GDMT, for specific cases, different medications, as well as device methods, should be considered. Unfortunately, some patients will eventually progress into the advanced stage (stage D) of HF. The general treatment in this stage of the disease consists mainly of inotropic medications and short-term and long-term mechanical circulatory support, with heart transplantation as the gold standard. Patients with advanced heart failure who are not eligible for heart transplantation or long-term mechanical circulatory support should be considered for palliative therapy."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["egységes, osztatlan"]},{"key":"dc:title","label":"Title","values":["Treatment approaches to chronic decompensated heart failure"]}]}],"canonical_facts":{"dc:contributor.advisor":["Pórszász, Róbert"],"dc:contributor.department":["DE--Általános Orvostudományi Kar"],"dc:creator":["Phan, Tai Anh Hao"],"dc:date.accessioned":["2023-05-11T11:21:45Z"],"dc:date.available":["2023-05-11T11:21:45Z"],"dc:description.abstract":["Heart failure remains, to this day, a clinical challenge for both patients and clinicians. For stage A and B patients, lifestyle changes, healthier diets, risk factors control, and comorbidities management are recommended. In stage C, aside from the general management in stages A and B are considered, medications like MRA, ACE-I, Beta-blockers, and SGLT2i, which are the four pillars of GDMT, should be recommended due to their great benefit on the disease’s outcome. Besides GDMT, for specific cases, different medications, as well as device methods, should be considered. Unfortunately, some patients will eventually progress into the advanced stage (stage D) of HF. The general treatment in this stage of the disease consists mainly of inotropic medications and short-term and long-term mechanical circulatory support, with heart transplantation as the gold standard. Patients with advanced heart failure who are not eligible for heart transplantation or long-term mechanical circulatory support should be considered for palliative therapy."],"dc:description.degree":["egységes, osztatlan"],"dc:identifier.uri":["https://hdl.handle.net/2437/353054"],"dc:language.iso":["en"],"dc:subject":["Chronic decompensated heart failure","Treatment"],"dc:title":["Treatment approaches to chronic decompensated heart failure"]},"updated_at":"2026-07-27T19:14:01Z"}